Emergent Biosolutions Inc. (NYSE:EBS) Director Sells $62,852.82 in Stock

Key Points

• Emergent Biosolutions Inc. Director Kathryn C. Zoon sold 7,086 shares of stock for a total of $62,852.82, decreasing her position by 8.98% and leaving her with 71,799 shares.
• The company's stock increased by 2.5% recently, trading at $9.06 with a market cap of $483.36 million.
• Wall Street Zen downgraded Emergent Biosolutions from a "buy" to a "hold" rating on August 9th, indicating a shift in analyst sentiment towards the stock.

Emergent Biosolutions Inc. (NYSE:EBS - Get Free Report) Director Kathryn C. Zoon sold 7,086 shares of the firm's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $8.87, for a total transaction of $62,852.82. Following the completion of the transaction, the director directly owned 71,799 shares in the company, valued at approximately $636,857.13. This represents a 8.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Emergent Biosolutions Stock Up 2.5%

Emergent Biosolutions stock traded up $0.22 during midday trading on Monday, hitting $9.06. 1,276,123 shares of the stock were exchanged, compared to its average volume of 1,257,272. Emergent Biosolutions Inc. has a 1 year low of $4.02 and a 1 year high of $13.28. The firm has a market cap of $483.36 million, a P/E ratio of 3.70 and a beta of 1.97. The company has a debt-to-equity ratio of 1.25, a current ratio of 5.66 and a quick ratio of 3.00. The company has a 50 day moving average price of $6.96 and a two-hundred day moving average price of $6.53.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.42. Emergent Biosolutions had a net margin of 16.38% and a return on equity of 24.63%. The firm had revenue of $140.90 million for the quarter, compared to the consensus estimate of $148.55 million. On average, sell-side analysts predict that Emergent Biosolutions Inc. will post -0.63 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Legal & General Group Plc acquired a new position in Emergent Biosolutions during the 2nd quarter valued at about $31,000. Ameritas Investment Partners Inc. bought a new stake in shares of Emergent Biosolutions in the 2nd quarter worth approximately $35,000. Raymond James Financial Inc. bought a new stake in shares of Emergent Biosolutions in the 2nd quarter worth approximately $53,000. Janney Montgomery Scott LLC bought a new stake in shares of Emergent Biosolutions in the 2nd quarter worth approximately $68,000. Finally, ProShare Advisors LLC bought a new stake in shares of Emergent Biosolutions in the 2nd quarter worth approximately $71,000. 78.40% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Wall Street Zen downgraded shares of Emergent Biosolutions from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.